EP Patent

EP3773532A1 — Levodopa fractionated dose composition and use

Assigned to Avion Pharmaceuticals LLC · Expires 2021-02-17 · 5y expired

What this patent protects

There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing …

USPTO Abstract

There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP3773532A1
Jurisdiction
EP
Classification
—
Expires
2021-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Avion Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.